Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
2022年3月9日 - 6:15AM
ビジネスワイヤ（英語）
In accordance with Articles L.233-8 II of
the French Commercial Code and 223-16 of the General Regulations of
the Autorité des Marchés Financiers (French Financial Markets
Authority)
Regulatory News:
Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN
code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA
Website: www.nanobiotix.com
Date
Number of Shares
Outstanding
Total number of voting
rights
Total voting rights, gross
(1)
Total voting rights, net
(2)
February 28, 2022
34,825,872
35,999,095
35,984,023
(1) The total number of gross (or “theoretical”) voting rights
is used as the basis for calculating threshold crossings. In
accordance with Article 223-11 of the AMF General Regulations, this
number is calculated on the basis of all shares to which voting
rights are attached, including those for which voting rights have
been suspended.
(2) The total number of net (or “exercisable at a Shareholders’
Meeting”) voting rights is calculated without taking into account
shares for which voting rights have been suspended. It is released
in order to ensure that the public is properly informed, in
accordance with the AMF recommendation of July 17, 2007.
***
About NANOBIOTIX: http://www.nanobiotix.com
Nanobiotix is a late-stage clinical biotechnology company
pioneering disruptive, physics-based therapeutic approaches to
revolutionize treatment outcomes for millions of patients;
supported by people committed to making a difference for
humanity.
The company’s philosophy is rooted in the concept of pushing
past the boundaries of what is known to expand possibilities for
human life. Incorporated in 2003, Nanobiotix is headquartered in
Paris, France. The company also has subsidiaries in Cambridge,
Massachusetts (United States), France, Spain, Switzerland, and
Germany. Nanobiotix has been listed on Euronext: Paris since 2012
and on the Nasdaq Global Select Market in New York City since
December 2020.
Nanobiotix is the owner of more than 30 umbrella patents
associated with three (3) nanotechnology platforms with
applications in 1) oncology; 2) bioavailability and
biodistribution; and 3) disorders of the central nervous
system.
The company's resources are primarily devoted to the development
of its lead product candidate–NBTXR3—which is the product of its
proprietary oncology platform and has already achieved market
authorization in Europe for the treatment of patients with soft
tissue sarcoma under the brand name Hensify®.
For more information about Nanobiotix, visit us at
http://www.nanobiotix.com or follow us on LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220308006210/en/
Nanobiotix
Nanobiotix Communications Brandon Owens VP,
Communications +1 (617) 852-4835 contact@nanobiotix.com
Nanobiotix Investor Relations Kate McNeil SVP, Investor
Relations +1 (609) 678-7388 investors@nanobiotix.com
Media Relations
France – Ulysse Communication Pierre-Louis Germain + 33
(0) 6 64 79 97 51 plgermain@ulysse-communication.com US – Porter
Novelli Dan Childs +1 (781) 888-5106
dan.childs@porternovelli.com
Nanobiotix (EU:NANO)
過去 株価チャート
から 10 2024 まで 11 2024
Nanobiotix (EU:NANO)
過去 株価チャート
から 11 2023 まで 11 2024
